US R&D Hub at Upper Providence

In 2014, R&D leadership announced significant changes to our business and ways of working with the aim of ensuring that we create an organization that is focused, simpler, and well-placed to deliver the key medicines coming through our pipeline. One of these changes included the consolidation of our facilities in two global R&D hubs with Upper Providence (UP) as the US Hub.

Our site

Located approximately 30 miles northwest of Philadelphia, the UP Hub establishes a vital footprint for GSK R&D and serves as a center of scientific excellence in the US market—the world’s largest healthcare market. Our site consists of 1,412,935 square feet and is situated on approximately 281 acres of land.

Our proximity to world-renowned academic centers, institutes, innovation centers and external partners allow the company to reinforce and build new relationships with key scientists and organizations, and establish GSK as the partner of choice. We have more than 1,500 collaborations globally with academia, public-private partnerships, biotech and pharma including many in the Philadelphia area.

Our people

Our people work collaboratively with the UK R&D Hub in Stevenage, satellite US offices in King of Prussia, Boston, North Carolina and San Diego, and our other global satellites. Collaboration is enabled by our SMART working approach. This includes open office and lab spaces, allowing visibility, communication, and interaction in order to drive innovation.

Collaboration extends beyond our site as employees are actively involved in the region through volunteering. For example, Science in Schools employee volunteer opportunities range from doing experiments at science festivals, judging science fairs and visiting local classrooms.

The current employee headcount in UP is 1600. Of this population, 50% of our employees are lab-based and 50% are office-based. By 2018 we expect our employee headcount to double to 3200.

Our work

By 2018, we will house the following areas of scientific research:
- HIV and Infectious Disease
- Oncology
- Immuno-inflammation
- Metabolic Pathways & Cardiovascular
- Dermatology

In addition to these areas of scientific research, we will also be home to the full range of R&D activities—from idea through manufacturing of the medicine. The site will house teams focused on target identification (disease selection), safety studies, active pharmaceutical ingredient (API) manufacture, clinical trial drug manufacture, clinical trial management, medical oversight and regulatory interactions, among many others.

Our goal

By concentrating into two major hubs (Stevenage UK and Upper Providence US) our goal is to bring world-class scientific excellence in a faster and more efficient way. Ultimately, our $245 million R&D investment to transform our Upper Providence site into the US R&D Hub helps us deliver on our mission:

To help people do more, feel better, live longer

November 2016